Abstract
RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus-host interactions and immunity contribute to the lack of biological countermeasures. This review updates the current understanding of RSV immunity and immunopathology with a focus on interferon responses, animal modeling, and correlates of protection.
Keywords:
RSV; host–pathogen interaction; immunity; immunopathology; respiratory syncytial virus.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adaptive Immunity
-
Animals
-
Disease Models, Animal
-
Humans
-
Immunity, Innate
-
Interferons / immunology
-
Interferons / metabolism
-
Respiratory Syncytial Virus Infections / epidemiology
-
Respiratory Syncytial Virus Infections / immunology*
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Virus Infections / virology*
-
Respiratory Syncytial Virus Vaccines / immunology
-
Respiratory Syncytial Virus, Human / immunology*
-
Respiratory Syncytial Virus, Human / physiology
Substances
-
Respiratory Syncytial Virus Vaccines
-
Interferons